Loading…
Veteran Federal Procurement Entrepreneurship Training Program Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · third_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI, avian flu outbreak (generally, no specific bill)
Read twice and referred to the Committee on Small Business and Entrepreneurship.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $247,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu (generally, no specific bill)
Client expense: $247,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · fourth_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI
Client expense: $255,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · fourth_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill)
Client expense: $255,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI
Client expense: $120,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · second_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, CURES 2.0 RFI
Client expense: $204,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2024 · second_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule
Client expense: $204,000 · Firm income: Not reported
2024 · first_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule
Client expense: $210,000 · Firm income: Not reported
2024 · first_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940), FDA proposed regulations regarding laboratory developed tests
Client expense: $210,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · third_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940)
Client expense: $162,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · third_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers)
Client expense: $162,000 · Firm income: Not reported
2023 · fourth_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940)
Client expense: $180,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · fourth_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers)
Client expense: $180,000 · Firm income: Not reported
2023 · third_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers)
Client expense: $162,000 · Firm income: Not reported
2023 · third_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940)
Client expense: $162,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · third_quarter · Medicare/Medicaid
Biosimilars. Pandemic and All-Hazards Preparedness Act (PAHPA). H.R.2369/S.2209 - VALID Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333)
Client expense: $195,000 · Firm income: Not reported
2023 · second_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940)
Client expense: $195,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · second_quarter · Medicare/Medicaid
Biosimilars. Pandemic and All-Hazards Preparedness Act (PAHPA). H.R.4128/S.2209 - VALID Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act, (PASTEUR Act-S.1355 /H.R. 2940)
Client expense: $150,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2023 · first_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act
Client expense: $150,000 · Firm income: Not reported
2023 · first_quarter · Health Issues
VALID Act (HR 4128/S 2209); General Issues related to data privacy and security
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Medicare/Medicaid
Biosimilars. Pandemic and All-Hazards Preparedness Act (PAHPA). H.R.4128/S.2209 - VALID Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE